ClinicalTrials.gg
Not yet recruitingNCT06581133Updated Nov 19, 2026

Sleep Disruption Pattern - Epilepsy Monitoring Unit

An interventional study of Alarm system in Epilepsy Intractable, sponsored by Duke University. Not yet recruiting. Open to participants aged 14 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Duke University · Not applicable, Interventional, and Other

How we know

Updated Nov 19, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
14 Years to 60 Years
Sex
All
01

Study summary

Epilepsy affects millions worldwide, with 40% of patients experiencing uncontrolled seizures despite medication. Comprehensive epilepsy centers recommend continuous video-electroencephalography monitoring to define seizure type and distinguish mimickers. This process, however, is resource-intensive, with lengthy hospital stays. The investigators' recent study identified a heightened association between arousals and epileptic activity in drug-resistant focal epilepsy patients. Building on these findings, the investigators aim to explore whether disrupting sleep with an alarm system triggers earlier occurrence of seizures, potentially offering insights to reduce hospital stay durations in epilepsy monitoring units.

02

Conditions studied

  • Epilepsy Intractable

Keywords

  • epilepsy monitoring unit
03

In context

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

This study's planned enrollment of 75 is above the median of 30 across 202 interventional studies indexed under Drug Resistant Epilepsy.

Browse Drug Resistant Epilepsy studies →

Lead sponsor

Duke University is the lead sponsor of 2,064 studies on the registry; 271 are open to participants now.

Of its 204 completed or terminated interventional studies of FDA-regulated products, 170 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 14 to 60 years
  • EMU monitoring for presurgical evaluations
  • Average 2-3 seizures per week based on pre-admission seizure diary
  • Sleep as a known seizure trigger

Exclusion criteria

Exclusion Criteria:

- Multiple seizures a day based on pre-admission seizure diary

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Alarm

    Patients in the alarm group will have an alarm system placed in their room, scheduled to sound at 4 timepoints during the night (specific timepoints adjusted based on patient's preferred bed times). This intervention will stop when the clinical team has collected sufficient seizures for clinical decision making.

    Device: Alarm system

  • No intervention
    Control

    Patients in the control group will have an alarm system placed in their room, but the alarm system will not sound during any of the nights during their EMU admission.

Interventions

  • DeviceAlarm system

    Generic alarm system programmed to sound during the night to try to induce arousals from sleep.

06

What researchers measure

Primary outcomes

  1. Seizure frequency during EMU (epilepsy monitoring unit) stay

    Average number of seizures per day, recorded daily during the patient's EMU stay. Measured for all groups of patients.

    Time frame: 1 month after the EMU stay (up to 9 weeks)

  2. Duration of EMU (epilepsy monitoring unit) admission

    Overall duration (in days) of the EMU admission. Measured for all groups of patients.

    Time frame: 1 month after the EMU stay (up to 9 weeks)

  3. Average interictal spike rates

    Average number of spike rates, taken from a random segment for each day and night. Measured for all groups of patients.

    Time frame: 1 month after the EMU stay (up to 9 weeks)

  4. Change in sleep quality

    As determined by changes in Pittsburgh Sleep Quality Index scores. A higher score indicates increased sleep disturbances.

    Time frame: Baseline (Day 1), last day of EMU stay (up to 5 weeks), 1 month after the EMU stay (up to 9 weeks)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Dec 2027, 11 months later.

Of 90 non-industry interventional studies with no phase under Drug Resistant Epilepsy, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 21. This study's planned 11 months is below that.

Counting every sponsor, half of 102 studies reached it within 34 months; a quarter within 21 and three quarters within 50.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2024
First posted
Sep 3, 2024
StartEst.
Jan 1, 2027was Oct 2026
Primary completionEst.
Dec 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 1, 2026→Jan 1, 2027
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Start date Oct 1, 2026→Jan 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06581133
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Sep 3, 2024
Start date
Jan 1, 2027 (estimated)
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Birgit Frauscher, MD PD
Contact
birgit.frauscher@duke.edu
9196139386
Mays Khweileh, MD
Contact
mays.khweileh@duke.edu
Birgit Frauscher, MD PD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion